Abbott Laboratories has completed a share repurchase tranche totaling approximately $1.35 billion, buying back 14,015,097 shares, including 11,599,094 shares between April and June 2026. The company's shares last closed at $107.81, with a 27.86% gain over the past 90 days, though year-to-date and one-year total shareholder returns are down 13.19% and 17.86%, respectively. Recent drivers include the completed buyback and the April acquisition of Exact Sciences, alongside lower 2026 guidance linked to earnings dilution from that deal. A popular narrative places Abbott's fair value at $119.13, suggesting the stock may be undervalued, while risks include pricing pressure in diagnostics and glucose monitoring, as well as potential earnings drag from tariffs and foreign exchange moves.
Abbott LaboratoriesCompleted $1.35 billion share buyback tranche, supporting stock price.
